2024
Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis.
Lain E, Bhatia N, Kircik L, Gold L, Harper J, Bunick C, Guenin E, Baldwin H, Feldman S, Rosso J. Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis. Journal Of Drugs In Dermatology 2024, 23: 873-881. PMID: 39361705, DOI: 10.36849/jdd.2024.8484.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsModerate-to-severe acneWeeks of once-daily treatmentInflammatory/noninflammatory lesion countsMild to moderate severityTriple-combination treatmentOnce-daily treatmentBaseline to weekPhase 3 studyTreatment success rateQuality-of-life improvementAcne-specific quality of lifePost hoc analysisCutaneous safety/tolerabilityFixed-doseVehicle gelDouble-blindNoninflammatory lesionsFemale acneNo significant differenceImpact of sexEfficacy measuresLesion countsAdverse eventsTreatment successTopical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances.
Del Rosso J, Bunick C, Kircik L, Bhatia N. Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances. Journal Of Drugs In Dermatology 2024, 23: 438-445. PMID: 38834223, DOI: 10.36849/jdd.8318.Peer-Reviewed Original ResearchConceptsAcne vulgarisTopical clindamycinTreatment of acne vulgarisManagement of acne vulgarisEmergence of antibiotic-resistant bacteriaAntibiotic-resistant bacteriaTopical agentsAnti-inflammatory propertiesTherapeutic advancesClindamycinClinical studiesTherapeutic outcomesClinical applicationAntimicrobial profileGram-positive bacteriaAnaerobic bacteriaMode of actionVulgarisMonotherapyPublished dataBacteriaTherapyAcneAntibiotics
2023
Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002–2016
Chang J, Nock M, Cohen J, Bunick C. Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002–2016. PLOS ONE 2023, 18: e0290763. PMID: 37733776, PMCID: PMC10513303, DOI: 10.1371/journal.pone.0290763.Peer-Reviewed Original ResearchConceptsTetracycline-class antibioticsDermatology visitsAdult acnePrescribed therapyNational Ambulatory Medical Care Survey dataNational Ambulatory Medical Care SurveyAge groupsAmbulatory Medical Care SurveyAdult female acneRetrospective database analysisEffectiveness of therapyAdult age groupsFemale acneJuvenile acneAdult female populationHealthcare utilizationHigher proportionDifferent pathogenesisCare SurveyAcne vulgarisAdult malesAcneAge 20Female populationDifferent presentationsSarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism
Lomakin I, Devarkar S, Patel S, Grada A, Bunick C. Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism. Nucleic Acids Research 2023, 51: 2915-2930. PMID: 36864821, PMCID: PMC10085706, DOI: 10.1093/nar/gkad103.Peer-Reviewed Original ResearchMeSH KeywordsAcne VulgarisAnti-Bacterial AgentsHumansPropionibacterium acnesProtein BiosynthesisRibosomesTetracyclinesTrends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016.
Grada A, Armstrong A, Bunick C, Salem R, Feldman S. Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016. Journal Of Drugs In Dermatology 2023, 22: 265-270. PMID: 36877883, DOI: 10.36849/jdd.7345.Peer-Reviewed Original ResearchMeSH KeywordsAcne VulgarisAnti-Bacterial AgentsDoxycyclineHumansMinocyclineRetrospective StudiesUnited StatesConceptsOral antibiotic useOral antibioticsAntibiotic useAntibiotic treatmentAcne treatmentHealth care claims dataOral antibiotic treatmentShort study durationIBM MarketScanPrimary outcomeGuideline recommendationsRetrospective studyAcne vulgarisRetrospective analysisClaims dataJ DrugsPatientsStudy durationAmerican AcademyTherapeutic classesSeparate occasionsDay gapMonthsAntibiotic resistanceAntibiotics
2022
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management
Daniele S, Kim S, Grada A, Moore A, Suozzi K, Bunick C. Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management. American Journal Of Clinical Dermatology 2022, 24: 199-223. PMID: 36539678, DOI: 10.1007/s40257-022-00746-4.Peer-Reviewed Original ResearchConceptsTruncal acne vulgarisAcne vulgarisTruncal acneHalf of patientsFacial acne vulgarisSignificant psychosocial burdenAvailable treatment optionsCommon skin disorderTreatment guidelinesPsychosocial burdenTreatment optionsTruncal involvementPatient managementFacial lesionsClinical problemSkin disordersUpper armCosmetic approachSebaceous glandsCurrent MedicalSkin areasPatientsAcneFocused reviewFurther investigation
2021
Sarecycline treatment for acne vulgaris: Rationale for weight‐based dosing and limited impact of food intake on clinical efficacy
Grada A, Del Rosso JQ, Graber E, Bunick CG, Gold L, Moore AY, Baldwin H, Obagi Z, Damiani G, Carrothers T, McNamee B, Hanze E. Sarecycline treatment for acne vulgaris: Rationale for weight‐based dosing and limited impact of food intake on clinical efficacy. Dermatologic Therapy 2021, 35: e15275. PMID: 34923732, PMCID: PMC9286649, DOI: 10.1111/dth.15275.Peer-Reviewed Original ResearchMeSH KeywordsAcne VulgarisAdministration, OralAnti-Bacterial AgentsEatingHumansMinocyclineTetracyclinesTreatment OutcomeConceptsTetracycline-class antibioticsWeight-based dosingHigh-fat mealClinical efficacyAcne vulgarisFood intakeWeight-based dosing protocolAcne vulgaris patientsLow clinical efficacyExposure-response modelingPopulation pharmacokinetic modelingAcne vulgaris treatmentHigh-fat foodsDosing protocolDosing recommendationsInflammatory lesionsVulgaris patientsExtent of exposureClinical studiesImproved complianceGastrointestinal absorptionVulgaris treatmentDrug AdministrationPharmacokinetic modelingEfficacy